eli lilly tirzepatide direct Eil announces Zepbound to be sold directly to consumers Lilly releases Zepbound® (tirzepatide) single-dose

Medications come from licensed 503A compounding pharmacies, serve all 50 states, require no insurance, and are HSA/FSA eligible

North American region is leading the GLP-1 agonists market.

Weight regain after stopping semaglutide affects most patients, with studies showing average weight recovery of 50-70% within one year of discontinuation

Cardiometabolic parameters during GLP-1 RA treatment GLP-1 RAs have also demonstrated important cardioprotective benefits that extend beyond their impact on BW loss

Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

To reduce stomach-related side effects, start by eating smaller portions